Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...

Verona Pharma (NASDAQ:VRNA – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $60.00 price target ...

Verona Pharma (NASDAQ:VRNA – Get Free Report) was upgraded by investment analysts at Roth Capital to a “strong-buy” rating in ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's ...

Verona Pharma reports $36M in Q4 and $42M in 2024 sales for Ohtuvayre, with over 16,000 prescriptions filled. Verona Pharma plc has announced its preliminary unaudited net product sales for ...

In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a renowned figure ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Verona Pharma. Looking at options history for Verona Pharma (NASDAQ:VRNA) we detected 14 trades. If we consider the ...